Abstract is: Bartha Maria Knoppers, OC OQ (born May 26, 1951) is a Canadian law Professor and an expert on the ethical aspects of genetics, genomics and biotechnology. Born in Hilversum, Netherlands, she received a Bachelor of Arts (French and English Literature) from McMaster University (1972), a Master of Arts degree in comparative literature from the University of Alberta (1974), Bachelor of Common Law (1978) and Civil Law (1981) degrees from McGill University, where she was selected as an Executive Editor for the McGill Law Journal, a Diploma of Legal Studies from University of Cambridge (1981), and a Doctorate of Laws from the University of Paris 1 Pantheon-Sorbonne (1985). In addition, she became a member of the Quebec Bar (1985). She was a professor at the Faculty of Law, Université de Montréal (1985-2009). Currently, she is Full Professor at the Department of Human Genetics, Faculty of Medicine, McGill University (2009-), and is an Associate Member of the Faculty of Law (2011) and the Biomedical Ethics Unit (2013). She is also the Director of the Centre of Genomics and Policy, McGill University (2009-), and the Founder and Chair of Public Population Project in Genomics (P3G) Consortium and CARTaGENE, Quebec (2003-2019). Prof. Knoppers has held the Canada Research Chair in Law and Medicine since 2001. This involves analyzing and developing of national and international policies, laws and guidelines in the field of genomics. She is Co-Founder of the Global Alliance for Genomics and Health (GA4GH) (2013-) and Co-Chair of the Governance Ethics Working Group for the Human Cell Atlas (HCA) (2018-). Previously, Prof. Knoppers was the Chair of the Ethics and Policy Committee of the International Cancer Genome Consortium (ICGC) (2009-2017), the Chair of the International Ethics Committee of the Human Genome Project (2012-2016), and the Chair of the Ethics Working Group of the World Anti-Doping Agency (WADA) (2016-2021). She was also a member of the Drafting Group for the Recommendation of the OECD Council on Health and Data Governance (2015-2016). Prof. Knoppers has published over 539 peer-reviewed articles, over 114 book chapters and 38 books. She is the lead author of the Stem Cell Charter (2010) and co-edited the Routledge Handbook of Medical Law and Ethics (2014). Her work has been featured in various peer-reviewed academic journals, such as SCIENCE, Nature, BMJ Open, Frontiers in Genetics, to name a few.
| human | Q5 |
| P3280 | BAnQ authority ID | 0000108078 |
| P268 | Bibliothèque nationale de France ID | 12288869j |
| P1670 | Canadiana Authorities ID (former scheme) | 0102C1963 |
| P11496 | CiNii Research ID | 1140282266644936320 |
| P1280 | CONOR.SI ID | 259859811 |
| P2456 | DBLP author ID | 117/5136 |
| P646 | Freebase ID | /m/06xkfq |
| P227 | GND ID | 124367097 |
| P269 | IdRef ID | 031726550 |
| P213 | ISNI | 0000000108881189 |
| P10553 | IxTheo authority ID | 085815829 |
| P11249 | KBR person ID | 13986155 |
| P244 | Library of Congress authority ID | n84081135 |
| P271 | NACSIS-CAT author ID | DA01658604 |
| P949 | National Library of Israel ID (old) | 002183104 |
| P8189 | National Library of Israel J9U ID | 987007421393205171 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 071403116 |
| P1015 | NORAF ID | 90375502 |
| P1207 | NUKAT ID | n2006005718 |
| P3762 | openMLOL author ID | 342095 |
| P496 | ORCID iD | 0000-0001-7004-2722 |
| P8951 | Order of Canada recipient ID | 146-297 |
| 146-297 | ||
| P12458 | Parsifal cluster ID | 871728 |
| P3987 | SHARE Catalogue author ID | 262861 |
| P214 | VIAF ID | 36981008 |
| P10832 | WorldCat Entities ID | E39PBJfxdRym4YKbjcFXBJWhpP |
| P166 | award received | Médaille du Barreau du Québec | Q3332367 |
| Jacques Rousseau Award | Q3404842 | ||
| Scientific of the year | Q3475807 | ||
| Fellow of the American Association for the Advancement of Science | Q5442484 | ||
| Officer of the Order of Canada | Q15278116 | ||
| P27 | country of citizenship | Canada | Q16 |
| P69 | educated at | University of Cambridge | Q35794 |
| University of Paris | Q209842 | ||
| McMaster University | Q632891 | ||
| University of Alberta | Q640694 | ||
| University of Paris 1 Pantheon-Sorbonne | Q999763 | ||
| McGill University Faculty of Law | Q14875553 | ||
| P108 | employer | McGill University | Q201492 |
| Université de Montréal | Q392189 | ||
| McGill University Health Centre | Q602748 | ||
| McGill University Faculty of Medicine and Health Sciences | Q6801306 | ||
| P734 | family name | Knoppers | Q6423018 |
| Knoppers | Q6423018 | ||
| Knoppers | Q6423018 | ||
| P101 | field of work | medical ethics | Q237151 |
| research ethics | Q1132684 | ||
| P735 | given name | Bartha | Q21142067 |
| Bartha | Q21142067 | ||
| P1412 | languages spoken, written or signed | French | Q150 |
| English | Q1860 | ||
| P106 | occupation | jurist | Q185351 |
| P21 | sex or gender | female | Q6581072 |
| Q91258010 | "CRISPR babies": What does this mean for science and Canada? |
| Q38682967 | "Matching" consent to purpose: The example of the Matchmaker Exchange. |
| Q42037215 | "Well-bear and well-rear" in China? |
| Q88759229 | 'Principled' personalized medicine? |
| Q91150561 | 'Serious' factor-a relevant starting point for further debate: a response |
| Q28686896 | A P3G generic access agreement for population genomic studies |
| Q64071603 | A Tale of Two Capacities: Including Children and Decisionally Vulnerable Adults in Biomedical Research |
| Q30488808 | A decision tool to guide the ethics review of a challenging breed of emerging genomic projects |
| Q28658438 | A human rights approach to an international code of conduct for genomic and clinical data sharing |
| Q115039399 | A marathon, not a sprint – neuroimaging, Open Science and ethics |
| Q88729575 | A new twist on an old problem: primary care physicians and results from direct-to-consumer genetic testing |
| Q108863418 | A policy Delphi study to validate the key implications of data sharing (KIDS) framework for pediatric genomics in Canada |
| Q91960210 | A response to "Personalised medicine and population health: breast and ovarian cancer" |
| Q28554316 | A review of the key issues associated with the commercialization of biobanks |
| Q57339871 | A roadmap for restoring trust in Big Data |
| Q24651939 | A second generation human haplotype map of over 3.1 million SNPs |
| Q43870708 | A step forward for data protection and biomedical research |
| Q57989224 | ACCE, Pharmacogenomics, and Stopping Clinical Trials: Time to Extend the CONSORT Statement? |
| Q46440223 | Abortion law in Francophone countries |
| Q89486025 | Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations |
| Q38380445 | Access Governance for Biobanks: The Case of the BioSHaRE-EU Cohorts |
| Q31078271 | An International Framework for Data Sharing: Moving Forward with the Global Alliance for Genomics and Health |
| Q37690269 | An ethics safe harbor for international genomics research? |
| Q35341406 | An implementation framework for the feedback of individual research results and incidental findings in research |
| Q22122153 | An integrated map of genetic variation from 1,092 human genomes |
| Q30581758 | An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. |
| Q38175582 | Anonymity 2.0: direct-to-consumer genetic testing and donor conception |
| Q31143296 | Are Data Sharing and Privacy Protection Mutually Exclusive? |
| Q48502696 | Are we asking the right ethics questions on drug shortages? Suggestions for a global and anticipatory ethics framework |
| Q28659644 | Attitudes of Canadian researchers toward the return to participants of incidental and targeted genomic findings obtained in a pediatric research setting |
| Q110986968 | Attitudes of Researchers to the Return of Incidental and Targeted Genomic Findings Obtained in a Research Setting to Participants |
| Q57642631 | Attitudes of parents toward the return of targeted and incidental genomic research findings in children |
| Q110986941 | Attitudes to the return of incidental and targeted genomic findings obtained in a high-risk pediatric cancer versus an inherited genetic condition research setting |
| Q60933652 | BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2 |
| Q34435782 | Beyond public health genomics: proposals from an international working group |
| Q50106440 | Beyond the permissibility of embryonic and stem cell research: substantive requirements and procedural safeguards |
| Q53315955 | Beyond the rhetoric: population genetics and benefit-sharing. |
| Q92017468 | Biobanking for Genomic and Personalized Health Research: Participant Perceptions and Preferences |
| Q36150035 | Biobanking: international norms |
| Q80313117 | Biobanks: simplifying consent |
| Q34028646 | Bioethics for clinicians: 14. Ethics and genetics in medicine |
| Q92131831 | Biotechnologies nibbling at the legal "human" |
| Q41816178 | Blurring lines. The research activities of direct-to-consumer genetic testing companies raise questions about consumers as research subjects |
| Q34039636 | Bridging consent: from toll bridges to lift bridges? |
| Q90460448 | Bridging stem cell research and medicine: a learning health system |
| Q114591775 | Bridging the European Data Sharing Divide in Genomic Science (Preprint) |
| Q96428971 | Bringing Code to Data: Don't Forget Governance |
| Q59069890 | Broaden human-rights focus for health data under GDPR |
| Q28652801 | Building a data sharing model for global genomic research |
| Q114297032 | COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight |
| Q41238392 | CRISPR germline engineering--the community speaks |
| Q33564494 | Can I be sued for that? Liability risk and the disclosure of clinically significant genetic research findings |
| Q92243153 | Canada's Assisted Human Reproduction Act: Pragmatic Reforms in Support of Research |
| Q83326843 | Catalyzing umbilical cord blood research in Canada: a survey of current needs and practices of principal investigators |
| Q34526631 | Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine |
| Q57250562 | Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine |
| Q92794686 | Clinical trial data sharing: here's the challenge |
| Q34306321 | Cohort profile of the CARTaGENE study: Quebec's population-based biobank for public health and personalized genomics |
| Q53047120 | Comparative Approaches to Biobanks and Privacy. |
| Q39213001 | Comparative Approaches to Genetic Discrimination: Chasing Shadows? |
| Q61970243 | Connective tissue: Cancer patients’ attitudes towards medical research using excised (tumour) tissue |
| Q28602211 | Consent Codes: Upholding Standard Data Use Conditions |
| Q53106433 | Consent and population genomics: the creation of generic tools. |
| Q57189717 | Consent recommendations for research and international data sharing involving persons with dementia |
| Q82473201 | Consent revisited: points to consider |
| Q41463323 | Consent to 'personal' genomics and privacy. Direct-to-consumer genetic tests and population genome research challenge traditional notions of privacy and consent |
| Q53572728 | Control of DNA samples and information. |
| Q91276934 | Correction to: Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations |
| Q97537027 | Correction to: Pandemics, privacy, and public health research |
| Q42127153 | Creating a data resource: what will it take to build a medical information commons? |
| Q46144260 | Criminal Prohibition of Wrongful Re‑identification: Legal Solution or Minefield for Big Data? |
| Q62066201 | Current trends in biobanking for rare diseases: a review [Corrigendum] |
| Q30485412 | Currents in contemporary bioethics. Open access as benefit sharing? The example of publicly funded large-scale genomic databases |
| Q39212492 | DNA sampling and informed consent |
| Q42759184 | DNA sampling and informed consent |
| Q26827422 | Data Safe Havens in health research and healthcare |
| Q36175174 | Data Sharing - Is the Juice Worth the Squeeze? |
| Q30979327 | Data analysis: Create a cloud commons |
| Q45935045 | Data protection and consent to biomedical research: a step forward? |
| Q28659060 | Data sharing in large research consortia: experiences and recommendations from ENGAGE |
| Q31011836 | Data sharing in stem cell translational science: policy statement by the International Stem Cell Forum Ethics Working Party |
| Q28727215 | Data sharing in the post-genomic world: the experience of the International Cancer Genome Consortium (ICGC) Data Access Compliance Office (DACO) |
| Q30860404 | Data sharing, year 1--access to data from industry-sponsored clinical trials |
| Q28748614 | DataSHIELD: resolving a conflict in contemporary bioscience--performing a pooled analysis of individual-level data without sharing the data |
| Q28649310 | DataSHIELD: taking the analysis to the data, not the data to the analysis |
| Q44556717 | Demystifying biobanks |
| Q47565969 | Developing Educational Resources to Advance Umbilical Cord Blood Banking and Research: A Canadian Perspective |
| Q51898907 | Developing registries of volunteers: key principles to manage issues regarding personal information protection: Figure 1 |
| Q56396024 | Development of a consent resource for genomic data sharing in the clinical setting |
| Q82470351 | Direct-to-consumer genetic testing: driving choice? |
| Q46015256 | Disclosure and management of research findings in stem cell research and banking: policy statement. |
| Q89292234 | Do It Yourself Newborn Screening |
| Q42598542 | Does policy grow on trees? |
| Q104797338 | Don Chalmers: His Contributions to Legal Research and Education, Health Law, and Research Ethics, Locally and Globally |
| Q31096700 | Don't Take It Personal: European Union Legal Aspects of Procuring and Protecting Environmental Exposure Data in Population Biobanks Through the Use of a Geo-Information-Systems Toolkit |
| Q74790840 | Donor insemination: children as in concreto or in abstracto subjects of rights? |
| Q44967970 | Duty to recontact: a legal harbinger? |
| Q57265347 | Editorial (An Idea Whose Time Has Come? An African Foresight Observatory on Genomics Medicine and Data-Intensive Global Science) |
| Q28708977 | Emerging issues in paediatric health research consent forms in Canada: working towards best practices |
| Q51773567 | Enabling pharmacogenomic clinical trials through sampling. |
| Q89799256 | Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives |
| Q52809057 | Epigenome-based cancer risk prediction: rationale, opportunities and challenges. |
| Q110787034 | Ethical and Analytic Challenges With Genomic Sequencing of Relapsed Hematologic Malignancies Following Allogeneic Hematopoietic Stem-Cell Transplantation |
| Q49132420 | Ethical and legal concerns: reproductive technologies 1990-1993. |
| Q114953031 | Ethical challenges and innovations in the dissemination of genomic data: the experience of the PERSPECTIVE project |
| Q100523608 | Ethical challenges of precision cancer medicine |
| Q42395049 | Ethical decision-making by hospital committees. |
| Q34586385 | Ethical dimensions of genetics in pediatric neurology: a look into the future |
| Q33804814 | Ethical guideposts for allelic variation databases |
| Q53367450 | Ethical issues in international collaborative research on the human genome: the HGP and the HGDP. |
| Q42016664 | Ethical issues in secondary uses of human biological materials from mass disasters |
| Q36737188 | Ethical issues involved in establishing a registry for familial Alzheimer's disease |
| Q58657038 | Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women's Cancer: Points to Consider |
| Q99716219 | Ethical, Legal, and Social Issues (ELSI) of Responsible Data Sharing Involving Children in Genomics: A Systematic Literature Review of Reasons |
| Q112827414 | Ethics and Big Data in health |
| Q41490835 | Ethics approval in applications for open-access clinical trial data: An analysis of researcher statements to clinicalstudydatarequest.com |
| Q36396290 | Ethics, big data and computing in epidemiology and public health |
| Q37004792 | Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer |
| Q37102122 | Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk |
| Q43082871 | Exposing participants? Population biobanks go geo. |
| Q48720081 | Extending the reach of public health genomics: what should be the agenda for public health in an era of genome-based and “personalized” medicine? |
| Q34000906 | FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project |
| Q28597289 | Facilitating a culture of responsible and effective sharing of cancer genome data |
| Q34326743 | Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information |
| Q104745334 | Failure to replicate the association of rare loss-of-function variants in type I IFN immunity genes with severe COVID-19 |
| Q53099117 | Fostering public cord blood banking and research in Canada. |
| Q28603879 | Framework for responsible sharing of genomic and health-related data |
| Q30388137 | Framing genomics, public health research and policy: points to consider |
| Q90626127 | From Poetry to Policy: An Interview with Bartha Maria Knoppers |
| Q35196954 | From banking to international governance: fostering innovation in stem cell research |
| Q33913473 | From genomic databases to translation: a call to action |
| Q28647502 | From the principles of genomic data sharing to the practices of data access committees |
| Q41818076 | From tissues to genomes |
| Q112817919 | GA4GH: International policies and standards for data sharing across genomic research and healthcare |
| Q53659160 | Genetic choices: a paradigm for prospective international ethics? |
| Q57455585 | Genetic database software as medical devices |
| Q37342368 | Genetic diagnosis of embryos: clear explanation, not rhetoric, is needed |
| Q35188990 | Genetic information and life insurance: a 'real' risk? |
| Q45258337 | Genetic information and the family: are we our brother's keeper? |
| Q34729102 | Genetic information and the law: constraints, liability and rights |
| Q41025113 | Genetic predisposition to cancer--issues to consider |
| Q51943800 | Genetic testing, legal capacity and adolescents. |
| Q83873165 | Genetic testing, physicians and the law: will the tortoise ever catch up with the hare? |
| Q74786196 | Genetic testing: a comparative view |
| Q57988743 | Genetically Enhanced Minors: Whose Responsibility? |
| Q115445072 | Geneticism and Germ Line: Between Courage and Caution |
| Q88638137 | Genome-based newborn screening: a conceptual analysis of the best interests of the child standard |
| Q23000444 | Genome-wide detection and characterization of positive selection in human populations |
| Q89081828 | Genome-wide sequencing in acutely ill infants: genomic medicine's critical application? |
| Q95262187 | Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe |
| Q36116641 | Genomic cloud computing: legal and ethical points to consider |
| Q37894579 | Genomic databases access agreements: legal validity and possible sanctions |
| Q27499767 | Genomic medicine: considerations for health professionals and the public |
| Q37404576 | Genomics and policymaking: from static models to complex systems? |
| Q89556898 | Genomics: data sharing needs an international code of conduct |
| Q86750183 | Genomics: from persons to populations and back again |
| Q34736416 | Genotype-driven recruitment: a strategy whose time has come? |
| Q55018570 | Geolocalisation of athletes for out-of-competition drug testing: ethical considerations. Position statement by the WADA Ethics Panel. |
| Q53191253 | Governing stem cell banks and registries: emerging issues. |
| Q47148198 | Harmonised consent in international research consortia: an impossible dream? |
| Q83141958 | Health privacy in genetic research |
| Q64092231 | Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease |
| Q90626136 | Heritable Genome Editing: Who Speaks for "Future" Children? |
| Q95841106 | How Can We Not Waste Legacy Genomic Research Data? |
| Q58660013 | How mutually recognizable is mutual recognition? An international terminology index of research ethics review policies in the USA, Canada, UK and Australia |
| Q115778930 | How to ensure the Human Cell Atlas benefits humanity |
| Q100414865 | How to fix the GDPR's frustration of global biomedical research |
| Q52737232 | Human gene editing: revisiting Canadian policy. |
| Q30664023 | Human genetic research, DNA banking and consent: a question of 'form'? |
| Q35998786 | Human genetic research: emerging trends in ethics |
| Q31153150 | Human genomic databases: a global public good? |
| Q48084795 | INTRODUCTION: From the Right to Know to the Right Not to Know |
| Q37746367 | INTRODUCTION: Harmonizing Privacy Laws to Enable International Biobank Research |
| Q28601541 | Identifiability and privacy in pluripotent stem cell research |
| Q64110931 | Importance of Participant-Centricity and Trust for a Sustainable Medical Information Commons |
| Q51530937 | Improving clinical trial sampling for future research - an international approach: outcomes and next steps from the DIA future use sampling workshop 2011. |
| Q57316278 | Informed Consent in Genetics |
| Q83818667 | Intellectual property rights in publicly funded biobanks: much ado about nothing? |
| Q48771949 | International Biobanking Summit V: Harmonizing Privacy Laws to Enable International Biobank Research. |
| Q28602512 | International Charter of principles for sharing bio-specimens and data |
| Q31108355 | International Charter of principles for sharing bio-specimens and data. |
| Q38433913 | International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases |
| Q37691049 | International ethics harmonization and the global alliance for genomics and health |
| Q81456584 | International initiatives |
| Q93334076 | International mHealth Research: Old Tools and New Challenges |
| Q24611474 | International network of cancer genome projects |
| Q45761882 | International normative perspectives on the return of individual research results and incidental findings in genomic biobanks |
| Q36884609 | Intrafamilial disclosure of risk for hereditary breast and ovarian cancer: points to consider |
| Q82511087 | Introduction: return of research results: how should research results be handled? |
| Q35476879 | Is rigorous retrospective harmonization possible? Application of the DataSHaPER approach across 53 large studies |
| Q56398210 | Key Implications of Data Sharing in Pediatric Genomics |
| Q92766557 | Legal and Ethical Challenges of International Direct-to-Participant Genomic Research: Conclusions and Recommendations |
| Q36088093 | Legal and ethical approaches to stem cell and cloning research: a comparative analysis of policies in Latin America, Asia, and Africa |
| Q37415290 | Legal approaches regarding health-care decisions involving minors: implications for next-generation sequencing |
| Q41911199 | Legal approaches regarding health-care decisions involving minors: implications for next-generation sequencing |
| Q42693448 | Legal aspects of genetic databases for international biomedical research: the example of the International Cancer Genome Consortium (ICGC). |
| Q52935354 | Legal aspects of genetics, work and insurance in North America and Europe. |
| Q44228695 | Legal regulation of cancer surveillance: Canadian and international perspectives |
| Q93012845 | Letter: Relearning the 3 R's? Reinterpretation, recontact, and return of genetic variants |
| Q42343135 | Life insurance: genomic stratification and risk classification |
| Q36261824 | Locus-specific databases: from ethical principles to practice |
| Q128275516 | Longitudinal Health Studies: Secondary Uses Serving the Future |
| Q30847112 | Maelstrom Research guidelines for rigorous retrospective data harmonization |
| Q34205284 | Managing incidental findings and research results in genomic research involving biobanks and archived data sets |
| Q53235893 | Mind the gap: policy approaches to embryonic stem cell and cloning research in 50 countries. |
| Q47771829 | Mitochondrial Replacement Therapy: The Road to the Clinic in Canada |
| Q92348294 | Model consent clauses for rare disease research |
| Q98164920 | Modeling consent in the time of COVID-19 |
| Q48778462 | Monetary payments for the procurement of oocytes for stem cell research: In search of ethical and political consistency |
| Q30905151 | Nature, nurture and exposure: Connecting biobank data with geographic data could yield public and individual health benefits, but risks to human rights need to be assessed |
| Q53288336 | Neuroethics, new ethics? |
| Q48239070 | Newborn genetic screening: ethical and social considerations for the nineties. |
| Q38947409 | Next-Generation Sequencing and the Return of Results |
| Q42139978 | Nutriproteomics and Proteogenomics: Cultivating Two Novel Hybrid Fields of Personalized Medicine with Added Societal Value |
| Q117476166 | Of Screening, Stratification, and Scores |
| Q53309759 | Of biotechnology and man. |
| Q42636949 | Of genomics and public health: Building public "goods"? |
| Q98506378 | Of the Rights and Best Interests of Future Generations |
| Q47429423 | One size does not fit all: toward "upstream ethics"? |
| Q48794550 | Oocyte donation for stem cell research. |
| Q106239596 | Open science and community norms |
| Q45951364 | Our social genome? |
| Q58590567 | Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials |
| Q38610568 | Oversight of Genomic Data Sharing: What Roles for Ethics and Data Access Committees? |
| Q87292473 | Oversight of human inheritable genome modification |
| Q56775340 | Paediatric biobanks: what makes them so unique? |
| Q36054009 | Paediatric research and the communication of not-so incidental findings |
| Q96766780 | Pandemics, privacy, and public health research |
| Q112724047 | Parental Access to Children's Raw Genomic Data in Canada: Legal Rights and Professional Responsibility |
| Q36417799 | Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges |
| Q57643559 | Pediatric research 'personalized'? International perspectives on the return of results |
| Q36543050 | Personalized medicine and access to health care: potential for inequitable access? |
| Q31033583 | Pharmacogenomic data sample collection and storage: ethical issues and policy approaches |
| Q36670996 | Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisited |
| Q37644192 | Physicians, genetics and life insurance |
| Q48515210 | Picard Lecture in Health Law--1992. Human genetics: parental, professional and political responsibility. |
| Q57316275 | Point-of-Care Genetic Tests for Infectious Disease: Legal Considerations |
| Q47657487 | Policies and strategies to facilitate secondary use of research data in the health sciences |
| Q33866156 | Policy and data-intensive scientific discovery in the beginning of the 21st century |
| Q53532851 | Policy forum: genetic technologies. Commercialization of genetic research and public policy. |
| Q38384682 | Population biobanking and international collaboration |
| Q38611712 | Population genetic testing for cancer susceptibility: founder mutations to genomes |
| Q39588665 | Population studies: return of research results and incidental findings Policy Statement |
| Q28727712 | Power to the people: a wiki-governance model for biobanks |
| Q58581904 | Pre-implantation Genetic Diagnosis: The Road Forward in Canada |
| Q41514882 | Precision medicine: a matter of regulation or collaboration? |
| Q36164685 | Preconception care and genetic risk: ethical issues |
| Q36489195 | Preimplantation genetic diagnosis: an overview of socio-ethical and legal considerations |
| Q26283296 | Prepublication data sharing |
| Q64044012 | Privacy-Preserving Linkage of Genomic and Clinical Data Sets |
| Q38782600 | Public variant databases: liability? |
| Q37595001 | Public-Private Partnerships in Cloud-Computing Services in the Context of Genomic Research |
| Q28742548 | Publishing SNP genotypes of human embryonic stem cell lines: policy statement of the International Stem Cell Forum Ethics Working Party |
| Q33683171 | Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies |
| Q42379128 | Questioning the limits of genomic privacy |
| Q28604024 | RESEARCH ETHICS. Ethics review for international data-intensive research |
| Q110987037 | RMGA Statement of Principles on the Return of Research Results and Incidental Findings |
| Q104794689 | Raising standards for global data-sharing-Response |
| Q30652877 | Rare diseases and now rare data? |
| Q109117034 | Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19 |
| Q30329077 | Rationale for an integrated approach to genetic epidemiology. |
| Q36087571 | Rationale, design, and methods for Canadian alliance for healthy hearts and minds cohort study (CAHHM) - a Pan Canadian cohort study |
| Q37041793 | Recent advances in medically assisted conception: legal, ethical and social issues |
| Q91860591 | Reciprocity and the Quest for Meaningful Disclosure |
| Q26995124 | Recommendations for returning genomic incidental findings? We need to talk! |
| Q128275405 | Reconciling the biomedical data commons and the GDPR: three lessons from the EUCAN ELSI collaboratory |
| Q34329302 | Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening |
| Q56764891 | Recontacting Pediatric Research Participants for Consent When They Reach the Age of Majority |
| Q34502444 | Recruiting terminally ill patients into non-therapeutic oncology studies: views of health professionals |
| Q30489911 | Registered access: a 'Triple-A' approach |
| Q56395225 | Registered access: authorizing data access |
| Q92766627 | Regulation of International Direct-to-Participant Genomic Research: Symposium Introduction |
| Q83629959 | Regulation of stem cell-based therapies in Canada: current issues and concerns |
| Q91819288 | Regulatory Landscape of International Direct-to-Participant (DTP) Genomic Research: Time to Untie the Gordian Knot? |
| Q80607653 | Regulatory approaches to reproductive genetic testing |
| Q88190924 | Reply to C Harling |
| Q38147064 | Reporting results from whole-genome and whole-exome sequencing in clinical practice: a proposal for Canada? |
| Q34411092 | Reproductive genetics: Canadian and European perspectives |
| Q47399144 | Reproductive technology and international mechanisms of protection of the human person. |
| Q35006914 | Research ethics and stem cells: Is it time to re-think current approaches to oversight? |
| Q21145862 | Research ethics recommendations for whole-genome research: consensus statement |
| Q48068534 | Research ethics. Children and population biobanks |
| Q53823189 | Research on Human Embryos and Reproductive Materials: Revisiting Canadian Law and Policy. |
| Q34117892 | Research priorities. ELSI 2.0 for genomics and society |
| Q61606051 | Responsible sharing of biomedical data and biospecimens via the "Automatable Discovery and Access Matrix" (ADA-M) |
| Q33545000 | Retrospective access to data: the ENGAGE consent experience |
| Q48936963 | Return of "accurate" and "actionable" results: yes! |
| Q38560292 | Return of genetic testing results in the era of whole-genome sequencing |
| Q61645954 | Return of individual genomic research results: are laws and policies keeping step? |
| Q53141951 | Return of results: towards a lexicon? |
| Q37397625 | Return of whole-genome sequencing results in paediatric research: a statement of the P3G international paediatrics platform |
| Q94024387 | Return of whole-genome sequencing results in paediatric research: a statement of the PG international paediatrics platform |
| Q34238585 | Returning incidental findings from genetic research to children: views of parents of children affected by rare diseases |
| Q37992134 | Sampling populations of humans across the world: ELSI issues |
| Q34611876 | Science and society: children and incompetent adults in genetic research: consent and safeguards |
| Q46538365 | Secondary Uses of Personal Data for Population Research. |
| Q38436063 | Serious genetic disorders: can or should they be defined? |
| Q36379200 | Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions |
| Q113208057 | Sharing and Safeguarding Pediatric Data |
| Q28586853 | Sharing health-related data: a privacy test? |
| Q36462742 | Should physicians warn patients' relatives of genetic risks? |
| Q24658616 | Special Issue - From Biobanks to the Clinic |
| Q47969754 | Stability of Attitudes to the Ethical Issues Raised by the Return of Incidental Genomic Research Findings in Children: A Follow-Up Study |
| Q57641728 | Statement of principles on the return of research results and incidental findings in paediatric research: a multi-site consultative process |
| Q37919074 | Steering vaccinomics innovations with anticipatory governance and participatory foresight |
| Q34334109 | Stem cell banking: between traceability and identifiability |
| Q48930042 | Stem cell charter |
| Q36960160 | Stem cell research ethics: consensus statement on emerging issues |
| Q28654693 | Stem cell research funding policies and dynamic innovation: a survey of open access and commercialization requirements |
| Q81608497 | Storing newborn blood spots: modern controversies |
| Q27797589 | Streamlining ethical review of data intensive research |
| Q115007438 | Streamlining ethics review for international health research |
| Q48036747 | Streamlining review of research involving humans: Canadian models |
| Q38602814 | Substitute consent to data sharing: a way forward for international dementia research? |
| Q37952318 | Sustained interaction: the new normal for stem cell repositories? |
| Q74817107 | The "legitimization" of artificial insemination: promise or problem? |
| Q92050809 | The 'serious' factor in germline modification |
| Q36166174 | The Adoption of Cloud Computing in the Field of Genomics Research: The Influence of Ethical and Legal Issues |
| Q45936245 | The Babel of genetic data terminology. |
| Q55241879 | The Canadian Partnership for Tomorrow Project: a pan-Canadian platform for research on chronic disease prevention. |
| Q34051873 | The Canadian Partnership for Tomorrow Project: building a pan-Canadian research platform for disease prevention |
| Q96955991 | The Genetic Family as Patient? |
| Q50108647 | The Genomic Commons |
| Q58664906 | The HUGO ethics committee: six innovative statements |
| Q104450645 | The Human Cell Atlas White Paper |
| Q43099018 | The Human Genome Organisation: towards next-generation ethics |
| Q36740769 | The Human Genome Project: under an international ethical microscope |
| Q92934063 | The Human Right to Science and the Regulation of Human Germline Engineering |
| Q90480160 | The Provision of Genetic Testing and Related Services in Quebec, Canada |
| Q84743971 | The art and science of biobanking |
| Q34318434 | The best interests of the child and the return of results in genetic research: international comparative perspectives |
| Q34676011 | The challenge of informed consent and return of results in translational genomics: empirical analysis and recommendations |
| Q48958917 | The changing landscape of human-animal chimera research: A Canadian regulatory perspective |
| Q35848496 | The clinical application of genome-wide sequencing for monogenic diseases in Canada: Position Statement of the Canadian College of Medical Geneticists |
| Q28743681 | The commercialization of genomic research in Canada |
| Q54010804 | The discombobulation of de-identification. |
| Q58674081 | The emergence of an ethical duty to disclose genetic research results: international perspectives |
| Q38233139 | The ethical framing of personalized medicine |
| Q28608069 | The ethics weathervane |
| Q57238658 | The expansion of newborn screening: is reproductive benefit an appropriate pursuit? |
| Q46965824 | The globalized gene. |
| Q53102441 | The human embryo: ethical and legal aspects. |
| Q110986933 | The impact of reporting magnetic resonance imaging incidental findings in the Canadian alliance for healthy hearts and minds cohort |
| Q48201446 | The sIRB System: A Single Beacon of Progress in the Revised Common Rule? |
| Q39984757 | The use of fresh embryos in stem cell research: ethical and policy issues |
| Q33774038 | To disclose, or not to disclose? Context matters |
| Q28716151 | Toward a roadmap in global biobanking for health |
| Q104795288 | Toward better governance of human genomic data |
| Q24264066 | Towards a data sharing Code of Conduct for international genomic research |
| Q53466450 | Towards a reconstruction of the "genetic family": new principles? |
| Q28598421 | Towards an ethics safe harbor for global biomedical research |
| Q84949693 | Trade-secret model: legal limitations |
| Q58662498 | Umbilical cord blood banking in Canada: socio-ethical and legal issues |
| Q82834668 | Umbilical cord blood stem cells: issues with private and public banks |
| Q80392642 | Understanding umbilical cord blood banking: what women need to know before deciding |
| Q59039810 | Unesco and population genetics |
| Q56780790 | Use of umbilical cord blood for stem cell research |
| Q45935576 | Vaccines of the 21st century and vaccinomics: data-enabled science meets global health to spark collective action for vaccine innovation. |
| Q30877354 | What are some of the ELSI challenges of international collaborations involving biobanks, global sample collection, and genomic data sharing and how should they be addressed? |
| Q34768361 | What are the most oppressing legal and ethical issues facing biorepositories and what are some strategies to address them? |
| Q90041969 | When information is the treatment? Precision medicine in healthcare |
| Q28645977 | Where Next for Genetics and Genomics? |
| Q41654153 | Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder |
| Q30391597 | Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics |
| Q30391601 | Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics |
| Q87524130 | Whole-genome sequencing in newborn screening programs |
| Q36695682 | Whole-genome sequencing in newborn screening? A statement on the continued importance of targeted approaches in newborn screening programmes |
| Q93147967 | Whose Commons? Data Protection as a Legal Limit of Open Science |
| Q117476187 | Women’s Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada |
| Q86016843 | [Personalized medicine: equity and access] |
| Q110987038 | noncc de principes du RMGA sur la communication des rrsultats de recherche et des ddcouvertes fortuites (RMGA Statement of Principles on the Return of Research Results and Incidental Findings) |
| Q75533882 | Open Science in Action | speaker | P823 |